6533b835fe1ef96bd129eaf4

RESEARCH PRODUCT

High-Sensitivity C-Reactive Protein and Statin Initiation

Esma R. IsenovicAndreja TrpkovicDanimir JevremovicSanja SoskicIvana ResanovicRizzo ManfrediJulijana Stanimirovic

subject

medicine.medical_specialtyStatinmedicine.drug_classInflammationBioinformaticsMultiple risk factorsRisk AssessmentPredictive Value of TestsRisk FactorsmedicineHumanscardiovascular diseasesDyslipidemiasInflammationbiologybusiness.industryPublic healthC-reactive protein3. Good healthCirculating biomarkersC-Reactive ProteinTreatment OutcomeCardiovascular DiseasesPractice Guidelines as TopicPhysical therapybiology.proteinBiomarker (medicine)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkers

description

The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.

yearjournalcountryeditionlanguage
2014-07-22Angiology
https://doi.org/10.1177/0003319714543000